Abbott Laboratories, maker of health-care products such as ranging from arthritis drugs to coronary stents, has announced it will invest in Singapore $300 million according to the Dow Jones Newswire.
The key driver of the Singapore investment strategy is to satisfy continued Asian demand for Abbott’s line of pediatric products.
The Abbott Singapore investment news comes just a month after the firm opened a new Singapore pharmaceutical R&D facility.
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment